摘要
目的探究冠心病介入治疗后氯吡格雷的应用效果以及对各类心血管不良事件的预防。方法选140例2018年9月至2019年9月在本院进行介入术治疗后的冠心病患者为研究对象,随机分为对照组和研究组,对照组70例患者实施低分子肝素联合阿司匹林治疗,选取阿司匹林肠溶片1 g,口服,每日1次,选取低分子肝素0.4 mL,给予患者皮下注射,每日1次。研究组70例患者在对照组基础上配合氯吡格雷治疗,阿司匹林治疗、低分子肝素治疗方法均与对照组相同,选取氯吡格雷75 mg,口服,每日1次,对比患者治疗前后D-二聚体水平以及血小板聚集率,统计患者治疗后血栓、心绞痛以及其他心血管不良事件的发生情况并比较两组生活质量。结果研究组患者治疗后D-二聚体水平、血小板聚集率以及心血管事件发生率均低于对照组,研究组患者治疗后SF-36生活质量评分均高于对照组,差异有统计学意义(均P<0.05)。结论介入术治疗后的冠心病患者在低分子肝素联合阿司匹林的基础上配合氯吡格雷,能够提高临床疗效,对于心血管不良事件的预防效果显著。
Objective To explore the application effect of clopidogrel after coronary artery disease interventional therapy and the prevention of various cardiovascular adverse events.Methods A total of 140 patients with coronary heart disease after interventional treatment in our hospital from September 2018 to September 2019 were randomly divided into control group and study group,seventy patients in the control group were treated with low molecular weight heparin combined with aspirin,aspirin enteric-coated tablet 1 g was taken orally,once a day,and low molecular weight heparin 0.4 mL was given subcutaneously,once a day.Seventy patients in the study group were treated with low molecular weight heparin combined with aspirin and clopidogrel.The methods of aspirin treatment and low molecular weight heparin treatment were the same as those in the control group.Clopidogrel 75 mg was selected orally,once a day.The incidence of thrombosis,angina pectoris and other adverse cardiovascular events after treatment was analyzed in two groups,and compared the quality of life between the two groups.Results D-two-mer level,platelet aggregation rate and the incidence of cardiovascular events in the study group were lower than those in the control group after treatment,and the SF-36 quality of life score in the study group was higher than that in the control group after treatment,and the differences were statistically significant(P<0.05).Conclusion Patients with coronary heart disease after interventional treatment with clopidogrel on the basis of low molecular weight heparin combined with aspirin can improve clinical efficacy and have a significant effect on the prevention of cardiovascular adverse events.
作者
栾鹏娇
LUAN Pengjiao(Department of Cardiology,Central Hospital of Yingkou Economic and Technological Development Zone(The Sixth People's Hospital of Yingkou City),Yingkou 115007,China)
出处
《中国医药指南》
2022年第31期95-97,共3页
Guide of China Medicine
关键词
氯吡格雷
冠心病
介入治疗
心血管不良事件
Clopidogrel
Coronary heart disease(CHD)
Interventional therapy
Adverse cardiovascular events
